Letter to the editor

Cutis

Volumn 79, Issue 1, 2007, Pages 57-58

  Elewski, Boni E ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Intendis Inc

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZELAIC ACID; DERMATOLOGICAL AGENT; DICARBOXYLIC ACID; METRONIDAZOLE;

DRUG ADMINISTRATION; HUMAN; NOTE; ROSACEA; SAFETY; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS; DERMATOLOGIC AGENTS; DICARBOXYLIC ACIDS; DRUG ADMINISTRATION SCHEDULE; HUMANS; METRONIDAZOLE; ROSACEA; SAFETY; TREATMENT OUTCOME;

EID: 33846887617     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Wolf JE Jr, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis. 2006;77(suppl 4): 3-11.
2. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139:1444-1450.
3. Czernielewski J, Liu Y. Comparison of 15% azelaic acid gel and 0.75% metronidazole gel for the topical treatment of papulopustular rosacea [letter]. Arch Dermatol. 2004;140:1282.
4. Elewski BE, Fleischer AB Jr, Pariser DM. Comparison of 15% azelaic acid gel and 0.75% metronidazole gel for the topical treatment of papulopustular rosacea [comment]. Arch Dermatol. 2004;140:1283.
5. Senn S. Statistical Issues in Drug Development. New York, NY: John Wiley and Sons; 1997:395.